Affinia Therapeutics, a preclinical biotech developing novel gene therapies for rare diseases and cancer, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
Affinia states that it is developing a novel class of treatments through its proprietary Affinia Rationally-designed Therapies platform, which focuses on the three key components of gene therapy: capsids, promoters, and manufacturing approaches. Its lead candidate, AFTX-001, is being developed for the treatment of metachromatic leukodystrophy. Its second candidate, AFTX-002, is being developed for the treatment of brain metastases secondary to HER2+ breast cancer. The company anticipates submitting INDs for these candidates in the 1H23 and 2H23, respectively.
The Waltham, MA-based company was founded in 2019 and booked $8 million in collaboration revenue for the 12 months ended September 30, 2021. It plans to list on the Nasdaq under the symbol AFTX. Goldman Sachs, Jefferies, Piper Sandler, and Chardan Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
